How early should blood pressure control be achieved for optimal cardiovascular outcomes

Journal of Human Hypertension

Volumn 25, Issue 4, 2011, Pages 211-217

  Weir, M R ^a,e   Zappe, D ^b   Orloski, L A ^c   Sowers, J R ^d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c OXFORD PHARMAGENESIS LTD   (United Kingdom)

^d University of Missouri   (United States)

^e UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

blood pressure; cardiovascular risk; chronic kidney disease; combination therapy; diabetes

Indexed keywords

AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; ATENOLOL; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; CANDESARTAN; CHLORTALIDONE; INDAPAMIDE PLUS PERINDOPRIL; LISINOPRIL; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RESPONSE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79952816587     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2010.64     Document Type: Article

References (33)

1. Lloyd-Jones D, Adams R, Carnethon M, de Simone G, Ferguson TB, Flegal K et al. Heart disease and stroke statistics-2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 2009; 119: e21-e181.
2. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens 2007; 25: 1105-1187. (Pubitemid 46924065)
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252. (Pubitemid 37553153)
4. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ et al. Reappraisal of European guidelines on hypertension management: a European society of hypertension task force document. Blood Press 2009; 18: 308-347.
5. Bakris GL, Sowers JR. ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich) 2008; 10: 707-713.
6. Sowers JR, Lastra G, Rocha R, Seifu Y, Crikelair N, Levy DG. Initial combination therapy compared with monotherapy in diabetic hypertensive patients. J Clin Hypertens (Greenwich) 2008; 10: 668-676.
7. Sowers JR, Neutel JM, Saunders E, Bakris GL, Cush-man WC, Ferdinand KC et al. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich) 2006; 8: 470-480.
8. Bakris GL, Weir MR. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) 2003; 5: 202-209. (Pubitemid 37428137)
9. Wong ND, Lopez VA, L'Italien G, Chen R, Kline SE, Franklin SS. Inadequate control of hypertension in US adults with cardiovascular disease comor-bidities in 2003-2004. Arch Intern Med 2007; 167: 2431-2436. (Pubitemid 350254901)
10. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-838. (Pubitemid 20113741)
11. Chatellier G, Ménard J. The absolute risk as a guide to influence the treatment decision-making process in mild hypertension. J Hypertens 1997; 15: 217-219. (Pubitemid 27129109)
12. Messerli FH. Safety of calcium antagonists: dissecting the evidence. Am J Cardiol 1996; 78: 19-23.
13. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angio-tensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-2997.
14. Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-convert-ing enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006; 48: 374-384. (Pubitemid 44253729)
15. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-2031. (Pubitemid 38781102)
16. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial. J Hypertens 2006; 24: 2163-2168. (Pubitemid 44611024)
17. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049-2051. (Pubitemid 38781107)
18. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodi-pine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906. (Pubitemid 41265663)
19. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875-886. (Pubitemid 36677151)
20. Basile JN, Chrysant S. The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens 2006; 20: 169-175.
21. Trenkwalder P, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Papademetriou V et al. The study on cognition and prognosis in the elderly (SCOPE)- major CV events and stroke in subgroups of patients. Blood Press 2005; 14: 31-37. (Pubitemid 40443751)
22. Bakris GL, Gaxiola E, Messerli FH, Mancia G, Erdine S, Cooper-DeHoff R et al. Clinical outcomes in the diabetes cohort of the international verapamil SR-trandolapril study. Hypertension 2004; 44: 637-642. (Pubitemid 39435232)
23. Black HR, Elliott WJ, Neaton JD, Grandits G, Grambsch P, Grimm Jr RH et al. Baseline characteristics and early blood pressure control in the convince trial. Hypertension 2001; 37: 12-18. (Pubitemid 32064233)
24. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international verapamil-trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816. (Pubitemid 37509488)
25. Jamerson K, Bakris GL, Dahlöf B, Pitt B, Velazquez E, Gupte J et al. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press 2007; 16: 80-86. (Pubitemid 47050368)
26. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et al. Benazepril plus amlodipine or hydrochlor-othiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
27. Weber MA, Jamerson K, Bakris GL, Yelazquez EJ, Dahlöf B, Kelly RY et al. Cardiovascular events in patients with diabetes and hypertension receiving renin angiotensin system blockade plus a diuretic or a calcium channel blocker. J Am Coll Cardiol 2010 (e-pub ahead of print 29 June 2010).
28. Kjeldsen SE, Jamerson KA, Bakris GL, Pitt B, Dahlöf B, Velazquez EJ et al. Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH Study. Blood Press 2008; 17: 7-17. (Pubitemid 351890487)
29. Bakris G, Hester A, Weber M, Dahlof B, Pitt B, Velasquez E et al. The diabetes subgroup baseline characteristics of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial. J Cardio-metab Syndr 2008; 3: 229-233.
30. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840. (Pubitemid 47362321)
31. Arguedas JA, Perez MI, Wright JM. Treatment blood pressure targets for hypertension. Cochrane Database Syst Rev 2009; 3: Art. No.: CD004349 (doi:10.1002/ 14651858.CD004349.pub2).
32. Kalaitzidis R, Bakris GL. Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich) 2009; 11: 345-347.
33. Weir MR, Levy D, Crikelair N, Rocha R, Meng X, Glazer R. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens 2007; 20: 807-815. (Pubitemid 46936176)